BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) Improves OutcomesFor Pancreatic Ductal Adenocarcinoma In Mouse Models 4/20/2015 12:06:33 PM
Pharmacyclics (PCYC) Release: IMBRUVICA (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, In Patients With Chronic Lymphocytic Leukemia (CLL) 4/20/2015 11:34:21 AM
AbbVie (ABBV) Extends Exchange Offer To Acquire Pharmacyclics (PCYC) 4/20/2015 9:28:49 AM
Pharmacyclics (PCYC) Release: New Longer-Term IMBRUVICA (ibrutinib) Data Show High Response Rates In Patients With Waldenstrom's Macroglobulinemia 4/9/2015 7:52:40 AM
Pharmacyclics (PCYC) Release: Solid Tumor Study Investigating Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Commences In Patients With Relapsed/Refractory Non-Small Cell Lung, Breast And Pancreatic Cancers 4/1/2015 8:31:26 AM
Pharmacyclics (PCYC) Release: New ibrutinib (IMBRUVICA) Data To Be Presented At American Association for Cancer Research Meeting 3/19/2015 10:17:29 AM
Pharmacyclics (PCYC) Release: Independent Data Monitoring Committee Unanimously Recommends Unblinding Of IMBRUVICA (Ibrutinib) Phase III Combination HELIOS Trial Based On Interim Analysis Showing Significant Improvement In Progression-Free Survival In Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma 3/17/2015 5:57:01 AM
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial 3/17/2015 5:56:00 AM
Inside The $21 Billion Bidding War For Pharmacyclics (PCYC) 3/6/2015 6:52:51 AM
AbbVie (ABBV) Overpaid in Pharmacyclics (PCYC) Deal, For Only 50% Rights to Imbruvica: Analyst 3/5/2015 12:45:43 PM
12345678910...